<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02881086</url>
  </required_header>
  <id_info>
    <org_study_id>GMALL08_2013</org_study_id>
    <nct_id>NCT02881086</nct_id>
  </id_info>
  <brief_title>Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment</brief_title>
  <official_title>Treatment Optimization in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment - a Phase IV-trial With a Phase III-part to Evaluate Safety and Efficacy of Nelarabine in T-ALL Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Goethe University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Goethe University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase IV study with the primary goal to optimize therapy of adult patients with acute
      lymphoblastic leukemia or lymphoblastic lymphoma (LBL) by dose and time intensive, pediatric
      based chemotherapy, risk adapted stem cell transplantation (SCT) and minimal residual disease
      (MRD) based individualised and intensified therapy. Study will further evaluate the role of
      asparaginase intensification, the extended use of rituximab and the use of nelarabine as
      consolidation therapy in T-ALL in a phase III-part of the study. Furthermore two
      randomisations will focus on the role of central nervous system (CNS) irradiation in
      combination with intrathecal therapy versus intrathecal therapy only in B-precursor ALL/LBL
      and the role of SCT in high-risk patients with molecular complete remission. Finally a new,
      dose reduced induction therapy in combination with Imatinib will be evaluated in Ph/BCR-ABL
      positive ALL.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">June 2025</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event free survival</measure>
    <time_frame>3.5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time until consolidation treatment I</measure>
    <time_frame>approximately 70 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Hematological remission rate</measure>
    <time_frame>after induction, approximately 6-8 weeks from diagnosis</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Molecular remission rate</measure>
    <time_frame>after induction and consolidation, approximately 6-8 weeks from diagnosis</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Results of the positron emission tomography (PET) based remission evaluation</measure>
    <time_frame>after consolidation, approximately 8-10 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Remission duration</measure>
    <time_frame>up to 10 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Relapse rate</measure>
    <time_frame>up to 10 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Overall survival</measure>
    <time_frame>up to 10 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Relapse location</measure>
    <time_frame>at timepoint of relapse (up to 10 years)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Early death</measure>
    <time_frame>during induction, approximately 6-8 weeks from diagnosis</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Death in clinical remission (CR)</measure>
    <time_frame>during treatment, up to approximately 2.5 years from diagnosis</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Comorbidities according to Charlson Score</measure>
    <time_frame>up to 2.5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Quality of life assessed by QLQ-C30</measure>
    <time_frame>up to 2.5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Eastern Cooperative Oncology Group (ECOG) under therapy</measure>
    <time_frame>up to 2.5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Toxicity assessed by CTCAE v4.03</measure>
    <time_frame>up to 2.5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Results of the Dementia Detection (DemTect) test</measure>
    <time_frame>up to 2.5 years</time_frame>
  </other_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">900</enrollment>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <condition>Lymphoblastic Lymphoma</condition>
  <arm_group>
    <arm_group_label>Stratification I - Standard Risk (SR)/ High Risk (HR)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Induction and consolidation I therapy for standard and high risk patients, PH/BCR-ABL-negative Chemotherapy, immunotherapy, intrathecal prophylaxis, CNS irradiation according to randomisation I Drugs: Rituximab, Vincristine, Daunorubicin, Dexamethasone, Cyclophosphamide, Cytarabine, Mercaptopurine, PEG-Asparaginase, Methotrexate, Vindesine, VP16</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stratification I - Philadelphia (PH)+</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Induction and consolidation I therapy for PH+ patients Chemotherapy, immunotherapy, intrathecal prophylaxis Drugs: Rituximab, Vincristine, Imatinib, Dexamethasone, PEG-Asparaginase, Cytarabine, Methotrexate, Vindesine, VP16</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rand I - B-Lin + CNS Rad + i.th. MTX</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Chemotherapy according to Stratification I SR/HR CNS prophylaxis: CNS irradiation 24 Gy, intrathecal Methotrexate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rand I - B-Lin + i.th. MTX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chemotherapy according to Stratification I SR/HR CNS prophylaxis: intrathecal Methotrexate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stratification II - SR + MRD-neg</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Chemotherapy, immunotherapy, intrathecal prophylaxis, consolidation II, reinduction, consolidation III - VI, maintenance Drugs: Rituximab, PEG-Asparaginase, Cytarabine, Methotrexate, Vindesine, Adriamycin, Prednisolone, Cyclophosphamide, Nelarabine, Dexamethasone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stratification II - HR + MRD-neg</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Chemotherapy or stem cell transplantation according to randomisation II</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stratification II - SR/HR/PH+ + MRD-pos</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Chemotherapy or targeted therapy, followed by stem cell transplantation Drugs: Fludarabine, Idarubicin, Cytarabine, Nelarabine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Randomisation II - HR + MRD-neg-SCT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Stem cell transplantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Randomisation II - HR + MRD-neg-SR-chemo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chemotherapy, immunotherapy, intrathecal prophylaxis, consolidation II, reinduction, consolidation III - VI, maintenance Drugs: Rituximab, Dexamethasone, PEG-Asparaginase, Cytarabine, Methotrexate, Vindesine, Adriamycin, Prednisolone, Cyclophosphamide, Nelarabine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <arm_group_label>Stratification I - Standard Risk (SR)/ High Risk (HR)</arm_group_label>
    <arm_group_label>Stratification I - Philadelphia (PH)+</arm_group_label>
    <arm_group_label>Stratification II - SR + MRD-neg</arm_group_label>
    <arm_group_label>Stratification II - HR + MRD-neg</arm_group_label>
    <arm_group_label>Randomisation II - HR + MRD-neg-SR-chemo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nelarabine</intervention_name>
    <arm_group_label>Stratification II - SR + MRD-neg</arm_group_label>
    <arm_group_label>Stratification II - HR + MRD-neg</arm_group_label>
    <arm_group_label>Stratification II - SR/HR/PH+ + MRD-pos</arm_group_label>
    <arm_group_label>Randomisation II - HR + MRD-neg-SR-chemo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEG-Asparaginase</intervention_name>
    <arm_group_label>Stratification I - Standard Risk (SR)/ High Risk (HR)</arm_group_label>
    <arm_group_label>Stratification I - Philadelphia (PH)+</arm_group_label>
    <arm_group_label>Stratification II - SR + MRD-neg</arm_group_label>
    <arm_group_label>Stratification II - HR + MRD-neg</arm_group_label>
    <arm_group_label>Randomisation II - HR + MRD-neg-SR-chemo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cranial irradiation</intervention_name>
    <arm_group_label>Rand I - B-Lin + CNS Rad + i.th. MTX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imatinib</intervention_name>
    <arm_group_label>Stratification I - Philadelphia (PH)+</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idarubicin</intervention_name>
    <arm_group_label>Stratification II - SR/HR/PH+ + MRD-pos</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <arm_group_label>Stratification I - Standard Risk (SR)/ High Risk (HR)</arm_group_label>
    <arm_group_label>Stratification I - Philadelphia (PH)+</arm_group_label>
    <arm_group_label>Stratification II - SR + MRD-neg</arm_group_label>
    <arm_group_label>Randomisation II - HR + MRD-neg-SR-chemo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <arm_group_label>Stratification I - Standard Risk (SR)/ High Risk (HR)</arm_group_label>
    <arm_group_label>Stratification II - SR + MRD-neg</arm_group_label>
    <arm_group_label>Stratification II - HR + MRD-neg</arm_group_label>
    <arm_group_label>Randomisation II - HR + MRD-neg-SR-chemo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <arm_group_label>Stratification II - SR/HR/PH+ + MRD-pos</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <arm_group_label>Stratification I - Standard Risk (SR)/ High Risk (HR)</arm_group_label>
    <arm_group_label>Stratification I - Philadelphia (PH)+</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mercaptopurine</intervention_name>
    <arm_group_label>Stratification I - Standard Risk (SR)/ High Risk (HR)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VP16</intervention_name>
    <arm_group_label>Stratification I - Standard Risk (SR)/ High Risk (HR)</arm_group_label>
    <arm_group_label>Stratification I - Philadelphia (PH)+</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daunorubicin (DNR)</intervention_name>
    <arm_group_label>Stratification I - Standard Risk (SR)/ High Risk (HR)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <arm_group_label>Stratification I - Standard Risk (SR)/ High Risk (HR)</arm_group_label>
    <arm_group_label>Stratification I - Philadelphia (PH)+</arm_group_label>
    <arm_group_label>Rand I - B-Lin + CNS Rad + i.th. MTX</arm_group_label>
    <arm_group_label>Rand I - B-Lin + i.th. MTX</arm_group_label>
    <arm_group_label>Stratification II - SR + MRD-neg</arm_group_label>
    <arm_group_label>Stratification II - HR + MRD-neg</arm_group_label>
    <arm_group_label>Randomisation II - HR + MRD-neg-SR-chemo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stem cell transplantation</intervention_name>
    <arm_group_label>Stratification II - HR + MRD-neg</arm_group_label>
    <arm_group_label>Randomisation II - HR + MRD-neg-SCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <arm_group_label>Stratification I - Standard Risk (SR)/ High Risk (HR)</arm_group_label>
    <arm_group_label>Stratification I - Philadelphia (PH)+</arm_group_label>
    <arm_group_label>Stratification II - SR + MRD-neg</arm_group_label>
    <arm_group_label>Stratification II - HR + MRD-neg</arm_group_label>
    <arm_group_label>Stratification II - SR/HR/PH+ + MRD-pos</arm_group_label>
    <arm_group_label>Randomisation II - HR + MRD-neg-SR-chemo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vindesine</intervention_name>
    <arm_group_label>Stratification I - Standard Risk (SR)/ High Risk (HR)</arm_group_label>
    <arm_group_label>Stratification I - Philadelphia (PH)+</arm_group_label>
    <arm_group_label>Stratification II - SR + MRD-neg</arm_group_label>
    <arm_group_label>Stratification II - HR + MRD-neg</arm_group_label>
    <arm_group_label>Randomisation II - HR + MRD-neg-SR-chemo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adriamycin</intervention_name>
    <arm_group_label>Stratification II - SR + MRD-neg</arm_group_label>
    <arm_group_label>Stratification II - HR + MRD-neg</arm_group_label>
    <arm_group_label>Randomisation II - HR + MRD-neg-SR-chemo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone</intervention_name>
    <arm_group_label>Stratification II - SR + MRD-neg</arm_group_label>
    <arm_group_label>Stratification II - HR + MRD-neg</arm_group_label>
    <arm_group_label>Randomisation II - HR + MRD-neg-SR-chemo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute lymphoblastic leukemia (pro-B, common, pre-B, early T, thymic T, mature T)

          -  Lymphoblastic lymphoma (B or T-lineage)

          -  Age 18-55 yrs

          -  Written informed consent

          -  Adequate contraception as specified per protocol

        Exclusion Criteria:

          -  Severe comorbidity or leukemia associated complications

          -  Late relapse of pediatric ALL or ALL as second malignancy

          -  Cytostatic pre-treatment

          -  Pregnancy or breast feeding

          -  Severe psychiatric illness or other circumstances which may compromise cooperation of
             the patient

          -  Participation in other clinical trials interfering with the study therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicola Gökbuget, Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Frankfurt (Main)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicola Gökbuget, Dr. med.</last_name>
    <phone>+496963016365</phone>
    <email>goekbuget@em.uni-frankfurt.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>GMALL Study center</last_name>
    <phone>+496963016366</phone>
    <email>gmall@em.uni-frankfurt.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital of Frankfurt (Main)</name>
      <address>
        <city>Frankfurt (Main)</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2016</study_first_submitted>
  <study_first_submitted_qc>August 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2016</study_first_posted>
  <last_update_submitted>March 2, 2018</last_update_submitted>
  <last_update_submitted_qc>March 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Goethe University</investigator_affiliation>
    <investigator_full_name>Nicola Goekbuget</investigator_full_name>
    <investigator_title>GMALL Head</investigator_title>
  </responsible_party>
  <keyword>Acute lymphoblastic leukemia</keyword>
  <keyword>Lymphoblastic lymphoma</keyword>
  <keyword>Nelarabine</keyword>
  <keyword>BCR-ABL</keyword>
  <keyword>MRD</keyword>
  <keyword>PEG-Asparaginase</keyword>
  <keyword>Rituximab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Pegaspargase</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Imatinib Mesylate</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
    <mesh_term>Idarubicin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Asparaginase</mesh_term>
    <mesh_term>6-Mercaptopurine</mesh_term>
    <mesh_term>Vindesine</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

